I

116TH CONGRESS
1ST SESSION

H. R. 5381

To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug to list the country of origin of each of the drug's active ingredients.

IN THE HOUSE OF REPRESENTATIVES

DECEMBER 10, 2019

Mr. DESJARLAIS introduced the following bill; which was referred to the Committee on Energy and Commerce

---

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug to list the country of origin of each of the drug's active ingredients.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "International Pharmaceutical Transparency Act of 2019".

SEC. 2. COUNTRY-OF-ORIGIN LABELING FOR ACTIVE INGREDIENTS IN DRUGS.

(a) MISBRANDING.—Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following:

''(ee) If it is a drug and its label fails to list the country of origin of each of its active ingredients.''.

(b) APPLICABILITY.—Section 502(ee) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies beginning on the day that is 6 months after the date of enactment of this Act.

○